Recent research have converged on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine neurotransmission. While GIP stimulators are increasingly employed for treating type 2 diabetes mellitus, their potential im